| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/01/2002 | US6335322 Therapeutic agents |
| 01/01/2002 | US6335321 Non-steroidal anti-inflammatory agent therapy for epithelial cell cancer |
| 01/01/2002 | US6335320 Method of treating fibrotic conditions |
| 01/01/2002 | US6335194 Antisense modulation of survivin expression |
| 01/01/2002 | US6335029 Polymeric coatings for controlled delivery of active agents |
| 01/01/2002 | US6335016 Chicken embryo lethal orphan (CELO) virus |
| 01/01/2002 | US6334445 Intravenously infusing a composition comprising a taxane into the human at continuous dosage over a period of 96 hours for therapy of ovarian cancer |
| 01/01/2002 | CA2142869C Trifluoromethylpyrroloindolecarboxylic acid ester and process for production thereof |
| 01/01/2002 | CA2083148C Bistriazenes as chemotherapeutic agents |
| 01/01/2002 | CA2048544C Intravascular embolizing agent containing angiogenesis-inhibiting substance |
| 12/29/2001 | CA2351904A1 Target |
| 12/29/2001 | CA2342059A1 Angiogenesis inhibitor |
| 12/27/2001 | WO2001098543A2 Method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 12/27/2001 | WO2001098511A1 Tumour-cell specific gene expression and its use in cancer therapy |
| 12/27/2001 | WO2001098506A2 Methods and means for regulation of gene expression |
| 12/27/2001 | WO2001098497A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | WO2001098493A1 Insulin-like growth factor-binding protein |
| 12/27/2001 | WO2001098490A1 A g-protein coupled receptor |
| 12/27/2001 | WO2001098489A1 Nucleotide and amino acid sequences of a cellular inhibitor of the dna replication in the epstein-barr herpes virus |
| 12/27/2001 | WO2001098483A1 Gene encoding novel protocadherin-like protein |
| 12/27/2001 | WO2001098473A2 Method for isolating and purifying a protein and resulting protein |
| 12/27/2001 | WO2001098468A2 Proteases |
| 12/27/2001 | WO2001098465A1 Cds1 GENE-KNOCKOUT CELLS AND MOUSE AND UTILIZATION THEREOF |
| 12/27/2001 | WO2001098363A2 Peptides for use in the immunotherapy of renal cell carcinoma |
| 12/27/2001 | WO2001098360A2 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | WO2001098359A2 Cyr61 as a target for treatment and diagnosis of breast cancer |
| 12/27/2001 | WO2001098357A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098351A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098350A2 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098343A2 Conserved diaphanous-related formin autoregulatory domain (dad) |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098307A1 Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098302A1 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer |
| 12/27/2001 | WO2001098299A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098290A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098278A1 Methods and compositions utilizing quinazolinones |
| 12/27/2001 | WO2001098277A2 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 12/27/2001 | WO2001098270A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098269A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098268A2 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098256A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| 12/27/2001 | WO2001097861A2 Vitronectin receptor antagonist pharmaceuticals |
| 12/27/2001 | WO2001097860A2 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 12/27/2001 | WO2001097859A1 Liposomal encapsulation of chelated actinium-225 and uses thereof |
| 12/27/2001 | WO2001097858A2 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| 12/27/2001 | WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | WO2001097849A1 Antitumor effect potentiators |
| 12/27/2001 | WO2001097848A2 Vitronectin receptor antagonist pharmaceuticals |
| 12/27/2001 | WO2001097844A1 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| 12/27/2001 | WO2001097843A2 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097828A2 Rhob as a suppressor of cancer cell growth and cell transformation |
| 12/27/2001 | WO2001097825A2 High molecular weight extracts of convolvulus arvensis (field bindweed) and polygonum convolvulus (wild buckwheat) |
| 12/27/2001 | WO2001097812A1 Tetracyclic compounds-containing pharmaceutical preparations |
| 12/27/2001 | WO2001097795A2 Systems and methods for treating a mucosal surface |
| 12/27/2001 | WO2001097790A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 12/27/2001 | WO2001097789A2 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors |
| 12/27/2001 | WO2001097618A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 12/27/2001 | WO2001097608A2 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods |
| 12/27/2001 | WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 12/27/2001 | WO2001070254A9 Use of human not1 and not1a orphan receptors |
| 12/27/2001 | WO2001064199A3 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 12/27/2001 | WO2001057042A3 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy |
| 12/27/2001 | WO2001055116A3 Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| 12/27/2001 | WO2001053505A3 Herpes virus strains for gene therapy |
| 12/27/2001 | WO2001053268A3 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 12/27/2001 | WO2001051608A3 Hybrid cells obtainable from antigen presenting cells |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001047564A3 Labelled ascorbic acid derivatives |
| 12/27/2001 | WO2001046256A3 Vesicle trafficking proteins |
| 12/27/2001 | WO2001042488A3 Plasminogen activator assay involving an elastase inhibitor |
| 12/27/2001 | WO2001038532A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 12/27/2001 | WO2001038490A3 ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| 12/27/2001 | WO2001034614A3 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 12/27/2001 | WO2001026693A3 Manufacture of polyglutamate-therapeutic agent conjugates |
| 12/27/2001 | WO2001023390A3 Azepinoindole derivatives, the production and use thereof |
| 12/27/2001 | WO2000064864A9 N-protected amines and their use as prodrugs |
| 12/27/2001 | US20010056184 Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds |
| 12/27/2001 | US20010056118 Induction of polymerization of tubulin and the stabilization of microtubules in cells by administering to the cancer cells an effective amount of dictyostatin-1 or derivatives or salt |
| 12/27/2001 | US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12 |
| 12/27/2001 | US20010056105 Useful as cosmetic for hair and body hygiene, and for treatment of dermatological complaints, with an inflammatory and/or immunoallergic component of rheumatic or respiratory type, cardivascular and opthalmogical disorders |
| 12/27/2001 | US20010056099 Method of reducing morbidity and the risk of mortality |
| 12/27/2001 | US20010056092 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 12/27/2001 | US20010056082 Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 12/27/2001 | US20010055758 Reagents and methods useful for detecting diseases of the prostate |
| 12/27/2001 | US20010055751 PSCA: Prostate stem cell antigen and uses thereof |
| 12/27/2001 | US20010055627 Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols |
| 12/27/2001 | US20010055616 Multilayer; active material core, enteric coating |
| 12/27/2001 | CA2414228A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | CA2414085A1 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 12/27/2001 | CA2414046A1 Conserved diaphanous-related formin autoregulatory domain (dad) |
| 12/27/2001 | CA2414015A1 Human receptors |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |